scholarly journals Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: a Systematic Review and Meta-Analysis

2018 ◽  
Vol 49 (3) ◽  
pp. 837-847 ◽  
Author(s):  
Guoxing Wan ◽  
Xue Sun ◽  
Fang Li ◽  
Xuanbin Wang ◽  
Chen Li ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Clinical Stage ◽  
Stage I ◽  
Metformin Therapy ◽  
Risk Of Death ◽  
Comprehensive Therapy

Background/Aims: Previous studies on the effect of metformin therapy on survival of pancreatic cancer patients obtained inconsistent findings. To reevaluate the prognostic value of metformin adjuvant treatment, a meta-analysis was carried out. Methods: Relevant articles addressing the association between metformin use and pancreatic cancer survival were electronically searched to identify eligible studies. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to assess the strength of the association. Results: Totally, seventeen studies involving 36791 participants were included. Overall, metformin use was found to be significantly associated with a favorable OS (HR=0.88, 95% CI=0.80-0.97). Subgroup analyses by ethnicity showed a significantly reduced risk of death for metformin users compared with non-users in Asians (HR=0.74, 95% CI=0.58-0.94) but nonsignificant in Caucasians. When stratified by clinical stage, a remarkable reduction of mortality risk in patients at stage I-II treated with metformin (HR=0.76, 95% CI=0.68-0.86) was found as well as the group at stage I-IV (HR=0.88, 95% CI=0.79-0.99), but not in patients at stage III-IV. In the stratification analyses based on treatment strategy, metformin therapy was found to be associated with a better clinical outcome in patients receiving surgery or comprehensive therapy (HR=0.73, 95% CI=0.62-0.87; HR=0.88, 95% CI=0.79-0.97) but not chemotherapy. However, the overall analysis failed to show a significant association between metformin use and DFS (HR=1.54, 95% CI=0.94 -2.50) with only 2 studies enrolled. Conclusion: The current study has evidenced a significant association of metformin adjuvant treatment with the survival benefit for pancreatic cancer patients, suggesting a potentially available option for the treatment. Further investigation is needed.

scholarly journals Sperm count in Swedish clinical stage I testicular cancer patients following adjuvant treatment

2019 ◽  
Vol 30 (4) ◽  
pp. 604-611 ◽  
Author(s):  
K. Weibring ◽  
C. Nord ◽  
O. Ståhl ◽  
J. Eberhard ◽  
K. Sandberg ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Sperm Count ◽  
Clinical Stage ◽  
Stage I

Sperm count in Swedish clinical stage I testicular cancer patients following modern adjuvant treatment.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 4542-4542
Author(s):  
Kristina Weibring ◽  
Carina Nord ◽  
Olof Stahl ◽  
Jakob Eberhard ◽  
Katinka Sandberg ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Patients ◽  
Adjuvant Treatment ◽  
Sperm Count ◽  
Clinical Stage ◽  
Stage I

scholarly journals Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (15) ◽  
pp. 25242-25250 ◽  
Author(s):  
Ping-Ting Zhou ◽  
Bo Li ◽  
Fu-Rao Liu ◽  
Mei-Chao Zhang ◽  
Qian Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Patients With Diabetes

scholarly journals Survival Benefit of Metformin Use for Pancreatic Cancer Patients Who Underwent Pancreatectomy: Results From a Meta-Analysis

2020 ◽  
Vol 7 ◽  
Author(s):  
Junqiang Zhang ◽  
Jichun Ma ◽  
Lingyun Guo ◽  
Bo Yuan ◽  
Zuoyi Jiao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Meta Analysis

Evaluation of the Safety and Feasibility of Laparoscopic Total Gastrectomy in Clinical Stage I Gastric Cancer Patients

2015 ◽  
Vol 39 (7) ◽  
pp. 1782-1788 ◽  
Author(s):  
Daisuke Ichikawa ◽  
Shuhei Komatsu ◽  
Takeshi Kubota ◽  
Kazuma Okamoto ◽  
Hirotaka Konishi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Total Gastrectomy ◽  
Clinical Stage ◽  
Laparoscopic Total Gastrectomy ◽  
Stage I ◽  
Gastric Cancer Patients

Sentinel Lymph Node Molecular Ultrastaging in Patients With Melanoma: A Systematic Review and Meta-Analysis of Prognosis

2007 ◽  
Vol 25 (12) ◽  
pp. 1588-1595 ◽  
Author(s):  
Simone Mocellin ◽  
Dave S.B. Hoon ◽  
Pierluigi Pilati ◽  
Carlo R. Rossi ◽  
Donato Nitti
Keyword(s):  
Meta Analysis ◽  
Clinical Stage ◽  
Prognostic Indicator ◽  
Hematologic Malignancies ◽  
Disease Recurrence ◽  
Tnm Stage ◽  
Stage I ◽  
Clinical Implementation ◽  
Recurrence Rates ◽  
Statistical Heterogeneity

Purpose Molecular biology-based ultrastaging of cancer is already part of the standard management of patients with hematologic malignancies, whereas the evidence for solid tumors is much more debated. Polymerase chain reaction (PCR) –based detection of melanoma cells in sentinel lymph nodes (SLN) of patients with melanoma represents an appealing prognostic tool. However, no consensus exists on the clinical implementation of this prognostic indicator for the management of these patients. Methods Twenty-two studies enrolling 4,019 patients who underwent SLN biopsy for clinical stage I to II cutaneous melanoma were reviewed. Correlation of PCR status with TNM stage, disease recurrence rates, and survival was assessed by means of association statistics and formal meta-analysis, respectively. Results PCR status correlated with both TNM stage (stage I to II v III; PCR positivity, 95.1% v 46.6%; P < .0001) and disease recurrence (PCR positive v negative; relapse rate, 16.8% v 8.7%; P < .0001). PCR positivity was also associated with worse overall (hazard ratio [HR], 5.08; 95% CI, 1.83 to 14.08; P = .002) and disease-free (HR, 3.41; 95% CI, 1.86 to 6.24; P < .0001) survival. Statistical heterogeneity was significant, underscoring the variability among overall effect estimates across studies; metaregression and subgroup analysis did not identify clear-cut sources of heterogeneity, although some study design variables were suggested as potential causes. Conclusion PCR status of SLN appears to have a clinically valuable prognostic power in patients with melanoma. Although the heterogeneity of the studies so far published warrants caution to avoid overestimating the favorable results of pooled data, our findings strongly support additional investigation in this field.

scholarly journals Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma—A Systematic Review and Meta-Analysis

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 291
Author(s):  
Anne Hendricks ◽  
Sophie Müller ◽  
Martin Fassnacht ◽  
Christoph-Thomas Germer ◽  
Verena A. Wiegering ◽  
...  
Keyword(s):  
Systematic Review ◽  
Adrenocortical Carcinoma ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Postoperative Mortality ◽  
Length Of Hospital Stay ◽  
Oncologic Outcome ◽  
Stage I ◽  
Tumor Stages ◽  
The Impact

(1) Background: Locoregional lymphadenectomy (LND) in adrenocortical carcinoma (ACC) may impact oncological outcome, but the findings from individual studies are conflicting. The aim of this systematic review and meta-analysis was to determine the oncological value of LND in ACC by summarizing the available literature. (2) Methods: A systematic search on studies published until December 2020 was performed according to the PRISMA statement. The primary outcome was the impact of lymphadenectomy on overall survival (OS). Two separate meta-analyses were performed for studies including patients with localized ACC (stage I–III) and those including all tumor stages (I–IV). Secondary endpoints included postoperative mortality and length of hospital stay (LOS). (3) Results: 11 publications were identified for inclusion. All studies were retrospective studies, published between 2001–2020, and 5 were included in the meta-analysis. Three studies (N = 807 patients) reported the impact of LND on disease-specific survival in patients with stage I–III ACC and revealed a survival benefit of LND (hazard ratio (HR) = 0.42, 95% confidence interval (95% CI): 0.26–0.68). Based on results of studies including patients with ACC stage I–IV (2 studies, N = 3934 patients), LND was not associated with a survival benefit (HR = 1.00, 95% CI: 0.70–1.42). None of the included studies showed an association between LND and postoperative mortality or LOS. (4) Conclusion: Locoregional lymphadenectomy seems to offer an oncologic benefit in patients undergoing curative-intended surgery for localized ACC (stage I–III).

Sign in / Sign up

Export Citation Format

Share Document